Intravitreal autologous plasmin as a therapeutic modality for diffuse diabetic macular edema

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 2063-2068

  Elsawy, Moataz F ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Autologous plasmin; Diabetic macular edema; Intravitreal injection; Triamcinolone

Indexed keywords

BEVACIZUMAB; CIPROFLOXACIN; DEXAMETHASONE; GLYCOSYLATED HEMOGLOBIN; PLASMIN; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE DURATION; FEMALE; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; MALE; OPHTHALMOLOGY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; VISUAL ACUITY;

EID: 84871325399     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s36609     Document Type: Article

References (26)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4-14.
2. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol. 2003;136:122-135.
3. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26:2653-2664.
4. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes. 2005;54:1615-1625.
5. Pober JS, Sessa WC. Evolving functions of endothelial cells in infammation. Nat Rev Immunol. 2007;7:803-815.
6. Sang DN, D'Amore PA. Is blockade of vascular endothelial growth factor benefcial for all types of diabetic retinopathy? Diabetologia. 2008;51:1570-1573.
7. Mignatti P, Rifkin DB. Plasminogen activators and matrix metallopro- teinases in angiogenesis. Enzyme Protein. 1996;49:117-137
8. Castellino FJ, Ploplis VA. Structure and function of the plasminogen/ plasmin system. Thromb Haemost. 2005;93:647-654.
9. Adibhatla RM, Hatcher JF. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets. 2008;7:243-253.
10. Lopez-Lopez F, Rodriguez-Blanco M, Gómez-Ulla F, Marticorena J. Enzymatic vitreolysis. Curr Diabetes Rev. 2009;5:57-62.
11. El-Asrar AM, Al-Mezain HS. Pharmacologic vitreolysis in diabetic retinopathy. Curr Pharm Biotechnol. 2011;12:406-409.
12. Díaz-Llopis M, Udaondo P, Arevalo F, et al. Intravitreal plasmin without associated vitrectomy as a treatment for refractory diabetic macular edema. J Ocul Pharmacol Ther. 2009;25:379-384.
13. Rizzo S, Pellegrini G, Benocci F, Belting C, Baicchi M, Vispi M. Autologous plasmin for pharmacologic vitreolysis prepared 1 hour before surgery. Retina. 2006;26:792-796.
14. Senturk F, Ozdemir H, Karacorlu M, Karacorlu SA, Uysal O. Microperimetric changes after intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion. Retina. 2010;30:1254-1261.
15. Khurieva-Sattler E, Krause M, Löw U, et al. Comparison of pars plana vitrectomy with ILM peeling and intravitreal triamcino- lone in diffuse diabetic macular edema. Klin Monbl Augenheilkd. 2010;227:496-500.
16. Díaz-Llopis M, Udaondo P, García-Delpech S, Cervera E, Salom D, Quijada A. Enzymatic vitrectomy by intravitreal autologous plasmin injection, as initial treatment for diffuse diabetic macular edema. Arch Soc Esp Oftalmol. 2008;83:77-84.
17. Sakuma T, Mizota A, Inoue J, Tanaka M. Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2010;150:876-882.
18. Udaondo P, Díaz-Llopis M, García-Delpech S, Salom D, Romero FJ. Intravitreal plasmin without vitrectomy for macular edema secondary to branch retinal vein occlusion. Arch Ophthalmol. 2011;129:283-287.
19. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr: Treatment with intravitreal steroid reduced blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthamol. 1992; 110(8):1155-1159.
20. Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and infammation: novel therapeutic targets. Middle East Afr J Ophthalmol. 2012; 19:52-59.
21. Boyer DS, Faber D, Gupta S, et al; Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31:915-923.
22. Elbendary AM, Shahin MM. Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema. Retina. 2011;31:2058-2064.
23. Gandorfer A. Objective of pharmacologic vitreolysis. Dev Ophthalmol. 2009;44:1-6.
24. Kramar M, Vu L, Whitson JT, He YG. The effect of intravitreal triamcinolone on intraocular pressure. Curr Med Res Opin. 2007;23: 1253-1258.
25. García Fernández M, García Alonso A, Fonollá Gil M, Rodríguez Villa S. Intravitreal triamcinolone acetonide use in diffuse persistent diabetic macular edema. Arch Soc Esp Oftalmol. 2011;86:314-319.
26. Bozkurt E, Kara N, Yazici AT, et al. Prophylactic selective laser tra- beculoplasty in the prevention of intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2011;152:976-981.